Overview
Polyrrhinia is an extremely rare congenital (present at birth) malformation in which a person is born with more than one nose or extra nose-like structures on the face. The name comes from the Greek words 'poly' meaning many and 'rhinia' referring to the nose. It falls under the broader category of congenital malformations of the nose, classified under ICD-10 code Q30.8 (other congenital malformations of the nose). Because this condition is so extraordinarily rare, very little medical literature exists about it, and most knowledge comes from isolated case reports throughout medical history. The extra nasal structure may vary in size and completeness — it can range from a small, partially formed bump to a more fully developed duplicate nose with nostrils and internal passages. The condition can affect breathing, appearance, and sometimes the normal development of surrounding facial structures. In some cases, it may be associated with other facial or midline developmental abnormalities. Treatment is primarily surgical. Reconstructive and plastic surgery can remove the extra nasal tissue and reshape the nose to achieve a more typical appearance and improve function. The timing and complexity of surgery depend on the size and anatomy of the extra structure, as well as whether it affects breathing or other functions. Because of its rarity, management is highly individualized and typically involves a multidisciplinary team of specialists.
Also known as:
Key symptoms:
Extra nose or nose-like structure on the faceAbnormal facial appearancePossible breathing difficultiesNasal obstruction or blockageUnusual facial symmetryPossible associated midline facial abnormalities
Clinical phenotype terms (9)— hover any for plain English
Neonatal
Begins at or shortly after birth (first 4 weeks)
FDA & Trial Timeline
10 eventsFar East Bio-Tec Co., Ltd — PHASE2
Sanofi — PHASE3
The Affiliated Hospital of Qingdao University — NA
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. — PHASE3
Sichuan Purity Pharmaceutical Technology Co., Ltd. — PHASE2
Longbio Pharma — PHASE2
Renmin Hospital of Wuhan University — NA
Desentum Oy — PHASE2
Guangdong Hengrui Pharmaceutical Co., Ltd — PHASE3
Genrix (Shanghai) Biopharmaceutical Co., Ltd. — PHASE3
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Polyrrhinia.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Polyrrhinia at this time.
New trials open frequently. Follow this disease to get notified.
Rare Disease Specialist
Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Polyrrhinia.
Community
No community posts yet. Be the first to share your experience with Polyrrhinia.
Start the conversation →Latest news about Polyrrhinia
Disease timeline:
New recruiting trial: A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
A new clinical trial is recruiting patients for Polyrrhinia
New recruiting trial: OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps
A new clinical trial is recruiting patients for Polyrrhinia
New recruiting trial: A Clinical Study on the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis
A new clinical trial is recruiting patients for Polyrrhinia
New recruiting trial: Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
A new clinical trial is recruiting patients for Polyrrhinia
New recruiting trial: Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
A new clinical trial is recruiting patients for Polyrrhinia
New recruiting trial: Study of Stapokibart Injection in Patients With Allergic Rhinitis
A new clinical trial is recruiting patients for Polyrrhinia
New recruiting trial: Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
A new clinical trial is recruiting patients for Polyrrhinia
New recruiting trial: First-in-man Single-dose and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy ofHY-133
A new clinical trial is recruiting patients for Polyrrhinia
New recruiting trial: Administration of Intranasal Midazolam for Anxiety in Palliative Care
A new clinical trial is recruiting patients for Polyrrhinia
New recruiting trial: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior
A new clinical trial is recruiting patients for Polyrrhinia
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What is the exact anatomy of my child's extra nasal structure, and does it contain internal passages?,When is the best time to perform corrective surgery?,How many surgeries might be needed over my child's lifetime?,Are there any other associated abnormalities we should check for?,Will my child have normal breathing after surgery?,What are the risks and potential complications of the surgery?,Should we see a geneticist to look for any underlying cause?
Common questions about Polyrrhinia
What is Polyrrhinia?
Polyrrhinia is an extremely rare congenital (present at birth) malformation in which a person is born with more than one nose or extra nose-like structures on the face. The name comes from the Greek words 'poly' meaning many and 'rhinia' referring to the nose. It falls under the broader category of congenital malformations of the nose, classified under ICD-10 code Q30.8 (other congenital malformations of the nose). Because this condition is so extraordinarily rare, very little medical literature exists about it, and most knowledge comes from isolated case reports throughout medical history. T
At what age does Polyrrhinia typically begin?
Typical onset of Polyrrhinia is neonatal. Age of onset can vary across affected individuals.
Which specialists treat Polyrrhinia?
5 specialists and care centers treating Polyrrhinia are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.